ARTICLE

UPDATE ON LUNG CANCER AND TREATMENT STRATEGIES

  1. HOME
  2. ARTICLE

01 Pages : 1-11

http://dx.doi.org/10.31703/giidr.2016(I-I).01      10.31703/giidr.2016(I-I).01      Published : Dec 2016

Update on Lung Cancer and Treatment Strategies

Abstract

    With the discovery of EGFR, it is now quite possible for the scientific world to treat patients with personalized medicine. Liquid biopsy is the invasive technique used to characterize human tumors by examining human body fluid. Different biomarkers are used to analyze tumor cells, but the most common of them is cell-free DNA. Liquid biopsy can identify tumor biomarkers to identify cancer of the lung at the start of the disease. In past studies, it was ascertained that plasma cfDNA concentration in patients with cancer is more in contrast to healthy persons. Numerous analytical ways have been synthesized to know molecular alteration through liquid biopsy. Molecular identification quantification assay as ddPCR make harmony in the detection of changes speed up against with a tumor biopsy. Different biomarkers that are used in liquid lung biopsy are Floating cfDNA and ctDNA, methylated ctDNA, CTCs in lung cancer, exosomes, TEP, and Circulating RNAs.

    cfRNA, ctDNA, Biomarkers, SCLC and NSCLC

    (1) Gul Shehnaz
    Chairperson, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.(Corresponding Author)
    (2) Akhtar Muhammad
    Undergraduates Students, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
    (3) Abdullah
    Undergraduates Students, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
    (4) Muhammad Ilyas
    Undergraduates Students, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
Fulltext PDF

References

  • Abdouh, M., Hamam, D., Gao, Z., Arena, V., Arena, M., & Arena, G. (2017). Exosomes isolated from cancer patients' sera transfer malignant traits and confer the same phenotype of primary tumors to oncosuppressor-mutated cells. Journal of Experimental & Clinical Cancer Research, 36(1). doi: 10.1186/s13046-017- 0587-0
  • Alhasan, A., Izuogu, O., Al-Balool, H., Steyn, J., Evans, A., & Colzani, M. et al. (2016). Circular RNA enrichment in platelets is a signature of transcriptome degradation. Blood, 127(9), e1-e11. doi: 10.1182/blood-2015-06-649434
  • Alix-Panabières, C., Mader, S., & Pantel, K. (2016). Epithelial-mesenchymal plasticity in circulating tumor cells. Journal of Molecular Medicine, 95(2), 133-142. doi:10.1007/ s00109-016-1500-6
  • Babayan, A., Alawi, M., Gormley, M., Müller, V., Wikman, H., & McMullin, R. et al. (2016). Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget, 8(34), 56066-56080. doi: 10.18632/oncotarget.10701
  • Bagheri, A., Khorshid, H., Tavallaie, M., Mowla, S., Sherafatian, M., & Rashidi, M. et al. (2018). A panel of noncoding RNAs in non-small- cell lung cancer. Journal of Cellular Biochemistry, 120(5), 8280-8290. doi: 10.1002/jcb.28111
  • Best, M., Sol, N., Kooi, I., Tannous, J., Westerman, B., & Rustenburg, F. et al. (2015). RNA-Seq of Tumor-Educated Platelets Enables Blood- Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell, 28(5), 666-676. doi: 10.1016/j.ccell.2015.09.018
  • Blakely, C. M., Watkins, T. B., Wu, W., Gini, B., Chabon, J. J., McCoach, C. E., ... & Rotow, J. (2017). Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature genetics, 49(12), 1693- 1704
  • Bredemeier, M., Edimiris, P., Mach, P., Kubista, M., Sjöback, R., & Rohlova, E. et al. (2017). Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer. Clinical Chemistry, 63(10), 1585- 1593. doi: 10.1373/clinchem.2016.269605
  • Coghlin, C. L., Smith, L. J., Bakar, S., Stewart, K. N., Devereux, G. S., Nicolson, M. C., & Kerr, K. M. (2010). Quantitative analysis of tumor in bronchial biopsy specimens. Journal of Thoracic Oncology, 5(4), 448-452
  • Chen, S., Zhao, J., Cui, L., & Liu, Y. (2017). Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clinical and Translational Oncology, 19(3), 332- 340.
  • Craene, B., & Berx, G. (2013). Regulatory networks defining EMT during cancer initiation and progression. NatureReviews Cancer, 13(2), 97-110. doi: 10.1038/ nrc3447
  • Diaz-Lagares, A., Mendez-Gonzalez, J., Hervas, D., Saigi, M., Pajares, M., & Garcia, D. et al. (2016). A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer. Clinical Cancer Research, 22(13), 3361-3371. doi: 10.1158/1078-0432.ccr-15-2346
  • Diaz Jr, L. A., & Bardelli, A. (2014). Liquid biopsies: genotyping circulating tumor DNA. Journal of clinical oncology, 32(6), 579.
  • Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J., Chirieac, L. R., ... & Doebele, R. C. (2017). Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 15(4), 504-535.
  • Fahrmann, J. F., Grapov, D., DeFelice, B. C., Taylor, S., Kim, K., Kelly, K., ... & Miyamoto, S. (2016). Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. Cancer Biomarkers, 16(4), 609- 617
  • Gai, W., & Sun, K. (2019). Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy. Genes, 10(1), 32
  • Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., ... & Lieber, D. S. (2018). Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature medicine, 24(9), 1441-1448.
  • Hanssen, A., Wagner, J., Gorges, T., Taenzer, A., Uzunoglu, F., & Driemel, C. et al. (2016). Characterization of different CTC subpopulations in non-small cell lung cancer. Scientific Reports, 6(1)
  • z, S., Bockhorst, J., Röder, C., Egberts, J., Schafmayer, C., & Küchler, T. et al. (2012). Disseminated Tumor Cells in the Bone Marrow Negatively Influence Survival after Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 19(8), 2539-2546
  • Hong, Y., Fang, F., & Zhang, Q. (2016). Circulating tumor cell clusters: What we know and what we expect (Review). International Journal of Oncology, 49(6), 2206-2216
  • International Journal of Cancer Research & Therapy, 2016. Lipid Peroxidation Serum Levels in Breast Cancer Patients. 1(1).
  • Joosse, S., & Pantel, K. (2015). Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. Cancer Cell, 28(5), 552-554
  • Kahlert, C., & Kalluri, R. (2013). Exosomes in tumor microenvironment influence cancer progression and metastasis. Journal of Molecular Medicine, 91(4), 431-437
  • Kharaziha, P., Ceder, S., Li, Q., & Panaretakis, T. (2012). Tumor cell-derived exosomes: A message in a bottle. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer, 1826(1), 103-111.
  • KONECNY, M., MARKUS, J., WACZULIKOVA, I., DOLESOVA, L., KOZLOVA, R., & REPISKA, V. et al. (2016). The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders. Neoplasma
  • Kneip, C., Schmidt, B., Seegebarth, A., Weickmann, S., Fleischhacker, M., & Liebenberg, V. et al. (2011). SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma. Journal of Thoracic Oncology, 6(10), 1632-1638
  • Lakka Klement, G., Yip, T., Cassiola, F., Kikuchi, L., Cervi, D., & Podust, V. et al. (2009). Platelets actively sequester angiogenesis regulators. Blood, 113(12), 2835-2842
  • Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., ... & Papadimitrakopoulou, V. A. (2019). Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clinical Cancer Research, 25(15), 4691-4700.
  • Lin, Y., Leng, Q., Jiang, Z., Guarnera, M. A., Zhou, Y., Chen, X., ... & Li, J. (2017). A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules. International journal of cancer, 141(6), 1240-1248
  • Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., ... & Kwiatkowski, D. J. (2018). Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Journal of Thoracic Oncology, 13(3), 323-358.
  • Liu, S., Zhan, Y., Luo, J., Feng, J., Lu, J., & Zheng, H. et al. (2019). Roles of exosomes in the carcinogenesis and clinical therapy of non- small cell lung cancer. Biomedicine & Pharmacotherapy, 111, 338-346.
  • Lu, S., Kong, H., Hou, Y., Ge, D., Huang, W., Ou, J., ... & Zhang, X. (2018). Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer, 123, 44-51
  • Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., ... & Louis, D. N. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129-2139
  • Ma, G., Zhang, J., Jiang, H., Zhang, N., Yin, L., Li, W., & Zhou, Q. (2017). Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non- small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 8(59), 99429.
  • Mahmood, M., Ward, C., Muller, H., Sohal, S., & Walters, E. (2017). Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease. Medical Oncology, 34(3)
  • McAllister, S., & Weinberg, R. (2014). The tumour- induced systemic environment as a critical regulator of cancer progression and metastasis. Nature Cell Biology, 16(8), 717- 727
  • McCusker, M. G., Russo, A., Scilla, K. A., Mehra, R., & Rolfo, C. (2019). How I treat ALK-positive non-small cell lung cancer. ESMO open, 4(Suppl 2), e000524
  • Mehlen, P., & Puisieux, A. (2006). Metastasis: a question of life or death. Nature Reviews Cancer, 6(6), 449-458
  • Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., ... & Nishiwaki, Y. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947- 957
  • Mouliere, F., Chandrananda, D., Piskorz, A., Moore, E., Morris, J., & Ahlborn, L. et al. (2018). Enhanced detection of circulating tumor DNA by fragment size analysis. Science Translational Medicine, 10(466), eaat4921
  • Muraoka, T., Soh, J., Toyooka, S., Aoe, K., Fujimoto, N., Hashida, S., ... & Yamamoto, H. (2013). The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer, 82(3), 485- 49
  • Newman, A., Bratman, S., To, J., Wynne, J., Eclov, N., & Modlin, L. et al. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 20(5), 548-554
  • Nilsson, R., Balaj, L., Hulleman, E., van Rijn, S., Pegtel, D., & Walraven, M. et al. (2011). Blood platelets contain tumor-derived RNA biomarkers. Blood, 118(13), 3680-3683
  • Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., ... & Naoki, K. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497-1500
  • Pennell, N. A., Arcila, M. E., Gandara, D. R., & West, H. (2019). Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. American Society of Clinical Oncology Educational Book, 39, 531-542
  • Ponomaryova, A. A., Rykova, E. Y., Cherdyntseva, N. V., Skvortsova, T. E., Dobrodeev, A. Y., ZavÂ’yalov, A. A., ... & Laktionov, P. P. (2013). Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer, 81(3), 397- 403
  • Ren, S., Zhang, S., Jiang, T., He, Y., Ma, Z., Cai, H., ... & Liu, X. (2018). Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology, 7(2), e1384108.
  • Revelo, A., Martin, A., Velasquez, R., Kulandaisamy, P., Bustamante, J., Keshishyan, S., & Otterson, G. (2019). Liquid biopsy for lung cancers: an update on recent developments. Annals Of Translational Medicine, 7(15), 349-349
  • Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., ... & Adamo, V. (2014). NSCLC and HER2: between lights and shadows. Journal of Thoracic Oncology, 9(12), 1750-1762
  • Rolfo, C., Mack, P. C., Scagliotti, G. V., Baas, P., Barlesi, F., Bivona, T. G., ... & Raez, L. E. (2018). Liquid biopsy for advanced non- small cell lung cancer (NSCLC): a statement paper from the IASLC. Journal of Thoracic Oncology, 13(9), 1248-1268
  • Roś-Mazurczyk, M., Wojakowska, A., Marczak, Ł., Polański, K., Pietrowska, M., Polańska, J., ... & Widłak, P. (2017). Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening-a pilot study. Acta Biochimica Polonica, 64(3), 513-518.
  • Rosell, R., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Cardenal, F., ... & Cobo, M. (2011). Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. Journal of clinical oncology, 29(15_suppl), 7503-7503
  • Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., ... & Insa, A. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine, 361(10), 958- 967
  • Santarpia, M., Liguori, A., D'Aveni, A., Karachaliou, N., Gonzalez-Cao, M., & Daffinà, M. et al. (2018). Liquid biopsy for lung cancer early detection. Journal Of Thoracic Disease, 10(S7), S882-S897.
  • Siegfried, J. (2005). E57. Estrogen receptor epidermal growth factor receptor interactions in lung cancer. Lung Cancer, 49, S89
  • Shen, S. Y., Singhania, R., Fehringer, G., Chakravarthy, A., Roehrl, M. H., Chadwick, D., ... & Kis, O. (2018). Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature, 563(7732), 579- 583.
  • Sourvinou, I., Markou, A., & Lianidou, E. (2013). Quantification of Circulating miRNAs in plasma. The Journal Of Molecular Diagnostics, 15(6), 827-834
  • Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Jänne, P. A., Koch, W. H., ... & Webb, A. (2016). Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus non-invasive blood- based analyses. Clinical Cancer Research, 22(5), 1103-1110.
  • Szpechcinski, A., Rudzinski, P., Kupis, W., Langfort, R., Orlowski, T., & Chorostowska- Wynimko, J. (2016). Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer letters, 374(2), 202- 207
  • StÃ¥hlberg, A., Krzyzanowski, P. M., Egyud, M., Filges, S., Stein, L., & Godfrey, T. E. (2017). Simple multiplexed PCR-based barcoding of DNA or ultrasensitive mutation detection by next-generation sequencing. nature protocols, 12(4), 664-682
  • Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., ... & Ercan, D. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non- small cell lung cancer harboring EGFR T790M. Nature medicine, 21(6), 560-562
  • Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., ... & Aggarwal, C. (2016). Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clinical Cancer Research, 22(23), 5772-5782
  • Thiery, J. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2(6), 442-454
  • Trudgen, K., Khattar, N. H., Bensadoun, E., Arnold, S., Stromberg, A. J., & Hirschowitz, E. A. (2014). Autoantibody profiling for lung cancer screening longitudinal retrospective analysis of CT screening cohorts. PLoS One, 9(2), e87947
  • Van Der Steen, N., Giovannetti, E., Pauwels, P., Peters, G. J., Hong, D. S., Cappuzzo, F., ... & Rolfo, C. (2016). cMET exon 14 skipping: from the structure to the clinic. Journal of Thoracic Oncology, 11(9), 1423-1432
  • Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J., & Lötvall, J. (2007). Exosome- mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9(6), 654-659
  • van der Pol, E., Böing, A., Harrison, P., Sturk, A., & Nieuwland, R. (2012). Classification, Functions, and Clinical Relevance of Extracellular Vesicles. Pharmacological Reviews, 64(3), 676-705
  • Vanni, I., Alama, A., Grossi, F., Dal Bello, M., & Coco, S. (2017). Exosomes: a new horizon in lung cancer. Drug Discovery Today, 22(6), 927- 936
  • Wang, Y., Li, L., Douville, C., Cohen, J. D., Yen, T. T., Kinde, I., ... & Wang, T. L. (2018). Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the
  • Wang, W., Song, Z., & Zhang, Y. (2017). A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer medicine, 6(1), 154-162
  • Weiss, G., Schlegel, A., Kottwitz, D., König, T., & Tetzner, R. (2017). Validation of the SHOX2/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. Journal of Thoracic Oncology, 12(1), 77-84.
  • Wu, H., Zhou, J., Mei, S., Wu, D., Mu, Z., & Chen, B. et al. (2016). Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. Journal Of Cellular And Molecular Medicine, 21(6), 1228-1236
  • Yoshida, T., Satouchi, M., Kurata, T., Nosaki, K., & Seto, T. (2016). O2-2-4Re-biopsy patterns among non-small cell lung cancer patients (pats) in Japan: a retrospective study. Annals of Oncology, 27(suppl_7
  • Yang, L., Ma, Y., Han, W., Li, W., Cui, L., Zhao, X., ... & Wang, H. (2015). Proteinase-activated receptor 2 promotes cancer cell migration through RNA methylation-mediated repression of miR-125b. Journal of Biological Chemistry, 290(44), 26627- 26637
  • Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X. Q., Wang, C., ... & Lu, S. (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. The lancet oncology, 12(8), 735- 742
  • Zhou, L., Lv, T., Zhang, Q., Zhu, Q., Zhan, P., & Zhu, S. et al. (2017). The biology, function and clinical implications of exosomes in lung cancer. Cancer Letters, 407, 84-92
  • Zheng, H., Zhan, Y., Liu, S., Lu, J., Luo, J., Feng, J., & Fan, S. (2018). The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. Journal Of Experimental & Clinical Cancer Research, 37(1
  • Zhang, T., & Armstrong, A. (2015). Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. Current Oncology Reports, 18(1).
  • Zomer, A., Maynard, C., Verweij, F., Kamermans, A., Schäfer, R., & Beerling, E. et al. (2015). In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior. Cell, 161(5), 1046- 1057

Cite this article

APA

CHICAGO

    CHICAGO : Shehnaz, Gul, Akhtar Muhammad, and Abdullah. 2016. "Update on Lung Cancer and Treatment Strategies." Global Immunological & Infectious Diseases Review, I (I): 1-11 doi: 10.31703/giidr.2016(I-I).01

HARVARD

    HARVARD : SHEHNAZ, G., MUHAMMAD, A. & ABDULLAH. 2016. Update on Lung Cancer and Treatment Strategies. Global Immunological & Infectious Diseases Review, I, 1-11.

MHRA

    MHRA : Shehnaz, Gul, Akhtar Muhammad, and Abdullah. 2016. "Update on Lung Cancer and Treatment Strategies." Global Immunological & Infectious Diseases Review, I: 1-11

MLA

    MLA : Shehnaz, Gul, Akhtar Muhammad, and Abdullah. "Update on Lung Cancer and Treatment Strategies." Global Immunological & Infectious Diseases Review, I.I (2016): 1-11 Print.

OXFORD

    OXFORD : Shehnaz, Gul, Muhammad, Akhtar, and Abdullah, (2016), "Update on Lung Cancer and Treatment Strategies", Global Immunological & Infectious Diseases Review, I (I), 1-11

TURABIAN

    TURABIAN : Shehnaz, Gul, Akhtar Muhammad, and Abdullah. "Update on Lung Cancer and Treatment Strategies." Global Immunological & Infectious Diseases Review I, no. I (2016): 1-11. https://doi.org/10.31703/giidr.2016(I-I).01